Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.
Saved in:
| Title: | Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer. |
|---|---|
| Authors: | Paschold L; Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Schultheiss C; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland., Schmidt-Barbo P; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.; Collaborative Research Institute Intelligent Oncology (CRIION), Freiburg, Germany., Klinghammer K; Department of Hematology and Oncology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Hahn D; Department of Hematology, Oncology, Stem-Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany., Tometten M; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany., Schafhausen P; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Blaurock M; Department of Otorhinolaryngology, Head and Neck Surgery, University Medicine Greifswald, Greifswald, Germany., Brandt A; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland., Westgaard I; Ultimovacs, Oslo, Norway., Kowoll S; Koordinierungszentrum für Klinische Studien Halle (KKS), Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Stein A; Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany., Hinke A; Clinical Cancer Research Consulting (CCRC), Düsseldorf, Germany., Binder M; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland. mascha.binder@unibas.ch.; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland. mascha.binder@unibas.ch.; Collaborative Research Institute Intelligent Oncology (CRIION), Freiburg, Germany. mascha.binder@unibas.ch. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2025 Aug 05; Vol. 9 (1), pp. 272. Date of Electronic Publication: 2025 Aug 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-025-01020-6 |
